FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-30 13:00 |
Faron Pharmaceuticals Ltd: Director/PCA Dealing
|
English | 27.2 KB | ||
| 2025-06-30 08:00 |
Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-…
|
English | 11.8 KB | ||
| 2025-06-12 08:00 |
Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2…
|
English | 13.2 KB | ||
| 2025-06-05 17:00 |
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Found…
|
English | 28.6 KB | ||
| 2025-06-03 13:00 |
Faron Pharmaceuticals Ltd: Registration of New Shares
|
English | 8.3 KB | ||
| 2025-06-03 08:00 |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 9.4 KB | ||
| 2025-06-02 08:00 |
Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025
|
English | 13.2 KB | ||
| 2025-05-30 08:00 |
Faron announces publication of full Phase I BEXMAB study data in Lancet Haemato…
|
English | 10.3 KB | ||
| 2025-05-27 18:00 |
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
|
English | 8.8 KB | ||
| 2025-05-27 08:00 |
Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potent…
|
English | 12.2 KB | ||
| 2025-05-23 08:00 |
Faron announces new data that highlight patient populations with cancer that ar…
|
English | 13.9 KB | ||
| 2025-05-21 08:00 |
Faron Appoints Ralph Hughes as Chief Business Officer (CBO)
|
English | 8.3 KB | ||
| 2025-05-15 08:00 |
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 20…
|
English | 8.6 KB | ||
| 2025-05-14 15:00 |
Faron Pharmaceuticals Ltd: Grant of Options
|
English | 22.5 KB | ||
| 2025-05-12 08:00 |
Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MD…
|
English | 12.6 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
